aod9604 phase 2 trial weight loss results AOD-9604 vs Semaglutide: 0% vs 15% Fat (2026 Data) AOD 9604 Peptide for Fat

Preclinical and early human data suggest it may promote lipolysis, inhibit lipogenesis, and preferentially act on adipose tissue by influencing beta3 adrenergicmediated pathways and hormonesensitive lipase activity

Its a more direct and reliable way to ensure your body gets exactly what it needs

The body clears it too quickly for it to build up significantly between doses, especially when compared to compounds with half-lives measured in days

Reconstitution & Handling Each 5 mg vial is typically reconstituted with 2 mL of bacteriostatic water, yielding a 2.5 mg/mL working stock, though investigators may adjust volumes based on study design and dosing precision needs

It allows the B12 to bind to fat molecules and be released slowly into body tissues

Continuous, uninterrupted use beyond 8 weeks has not been characterized in any published model